Novel Tx for chronic sinusitis.
The U.S. Food and Drug Administration (FDA) has approved Intersect ENT's Premarket Approval (PMA) application for its Propel[TM] mometasone furoate implant, which offers localized, controlled drug delivery for patients with chronic sinusitis.
The implant, which is inserted by the physician after endoscopic sinus surgery, delivers steroid directly to the sinus tissue. The spring-like implant expands to prop open the sinus and gradually delivers an advanced corticosteroid with anti-inflammatory properties directly to the sinus lining to maintain sinus patency.
According to the company, this system has been clinically proven to prevent obstruction of the ethmoid sinus after surgery, improving postoperative outcomes and reducing the need for additional surgery and systemic steroids. The implant's safety and efficacy have been studied in three prospective clinical trials.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||treatment; Intersect ENT; PRODUCT MARKETPLACE|
|Comment:||Novel Tx for chronic sinusitis.(treatment)(Intersect ENT)(PRODUCT MARKETPLACE)|
|Publication:||Ear, Nose and Throat Journal|
|Article Type:||Brief article|
|Date:||Oct 1, 2011|
|Previous Article:||Point-of-care CT system.|
|Next Article:||Speech, language, and voice disorders.|